Reuters
10 Jun 2026, 06:38 UTC · 2h ago
Sanofi ends Phase 3 riliprubart trial after weak interim results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
Reuters
10 Jun 2026, 06:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
What the story claims
1 claim · each scored for market impact
Sanofi is stopping the Phase 3 trial of riliprubart for a rare neurological condition due to insufficient efficacy. — The failure of a late-stage clinical trial represents a lost investment and the removal of a potential future revenue stream.
-0.60Which stocks this story touches
The company is stopping a Phase 3 trial of riliprubart due to insufficient efficacy.
Continue reading
6 related stories
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
PRNewsWire
2h ago
